David Rometo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Rometo has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Mary T. Korytkowski
Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
2 shared publications - Chevon M. Rariy
Division of Endocrinology, Diabetes, and Metabolism, University of Pittsburgh Medical Center (UPMC), 200 Lothrop Avenue, Pittsburgh, PA, 15225, USA.
1 shared publication - Francesca Galbiati
Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114
1 shared publication Hussain Mahmud
Department of Medicine Division of Endocrinology, Diabetes, and Metabolism University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
1 shared publication- Lizeth Cifuentes
Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, USA
1 shared publication
Latest Publications
- Open Access
- 20 November 2023
- Published by Wiley in Obesity Science & Practice
- Vol. 10 (1) , e722
Weight regain after total meal replacement very low‐calorie diet program with and with‐out anti‐obesity medications
Background: Very low‐calorie diets (VLCDs) employing total meal replacement (TMR) offer substantial short‐term weight loss. Concurrently, anti‐obesity medications (AOMs) have shown promise as adjunctive treatments when combined with VLCDs.Aims: This study aimed to investigate the impact of adjuvant AOMs on weight loss and weight regain within a comprehensive lifestyle program.Methods: This is a retrospective study of patients with obesity enrolled in VLCD/TMR programs, specifically the OPTIFAST program.Results: Data from 206 patients (68% women, mean age 52.39 ± 13.05 years, BMI 41.71 ± 7.04 kg/m2) were analyzed. Of these, 139 received no AOM (AOM‐), while 67 received AOMs (AOM+). Total body weight loss percentages (TWL%) at 6 and 18 months were −17.87% ± 7.02 and −12.10% ± 11.56, respectively. There was no significant difference in 6‐month weight loss between the AOM groups. However, the AOM + group exhibited lower weight regain (3.29 kg ± 10.19 vs. 7.61 kg ± 11.96; p = 0.006) and weight regain percentage (WR%) (31.5% ± 68.7 vs. 52.16% ± 64.4; p = 0.04) compared with the AOM‐ group.Conclusion: The findings highlighted the potential of AOMs and VLCD/TMR as effective strategies for long‐term weight management in individuals with obesity.
- 20 November 2023
- Published by Wiley in Obesity Science & Practice
- Vol. 10 (1) , e722
Open AccessWeight regain after total meal replacement very low‐calorie diet program with and with‐out anti‐obesity medications
Background: Very low‐calorie diets (VLCDs) employing total meal replacement (TMR) offer substantial short‐term weight loss. Concurrently, anti‐obesity medications (AOMs) have shown promise as adjunctive treatments when combined with VLCDs.Aims: This study aimed to investigate the impact of adjuvant AOMs on weight loss and weight regain within a comprehensive lifestyle program.Methods: This is a retrospective study of patients with obesity enrolled in VLCD/TMR programs, specifically the OPTIFAST program.Results: Data from 206 patients (68% women, mean age 52.39 ± 13.05 years, BMI 41.71 ± 7.04 kg/m2) were analyzed. Of these, 139 received no AOM (AOM‐), while 67 received AOMs (AOM+). Total body weight loss percentages (TWL%) at 6 and 18 months were −17.87% ± 7.02 and −12.10% ± 11.56, respectively. There was no significant difference in 6‐month weight loss between the AOM groups. However, the AOM + group exhibited lower weight regain (3.29 kg ± 10.19 vs. 7.61 kg ± 11.96; p = 0.006) and weight regain percentage (WR%) (31.5% ± 68.7 vs. 52.16% ± 64.4; p = 0.04) compared with the AOM‐ group.Conclusion: The findings highlighted the potential of AOMs and VLCD/TMR as effective strategies for long‐term weight management in individuals with obesity.
- 15 February 2016
- Published by Springer Nature in Current Diabetes Reports
- Vol. 16 (4) , 1-8
Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery
Bariatric surgery in patients with type 2 diabetes has been shown to improve glycemic control and reduce need for glucose-lowering medications. Some of these improvements occur in the early postoperative period prior to any weight loss. These early reductions in circulating glucose can be attributed to primarily perioperative caloric restriction and prolonged fasting. Inpatient glycemic targets for patients undergoing bariatric surgery are similar to those recommended for other surgical procedures as a way of minimizing risk for complications. There is evidence that achieving perioperative and postoperative glycemic targets can improve the ability to achieve remission of type 2 diabetes following gastric bypass surgery. This review provides recommendations regarding glycemic goals, strategies for achieving these goals with minimal risk for hypoglycemia, and an examination of the data suggesting an association between perioperative glycemic management and diabetes remission following bariatric surgery.
- 15 February 2016
- Published by Springer Nature in Current Diabetes Reports
- Vol. 16 (4) , 1-8
Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery
Bariatric surgery in patients with type 2 diabetes has been shown to improve glycemic control and reduce need for glucose-lowering medications. Some of these improvements occur in the early postoperative period prior to any weight loss. These early reductions in circulating glucose can be attributed to primarily perioperative caloric restriction and prolonged fasting. Inpatient glycemic targets for patients undergoing bariatric surgery are similar to those recommended for other surgical procedures as a way of minimizing risk for complications. There is evidence that achieving perioperative and postoperative glycemic targets can improve the ability to achieve remission of type 2 diabetes following gastric bypass surgery. This review provides recommendations regarding glycemic goals, strategies for achieving these goals with minimal risk for hypoglycemia, and an examination of the data suggesting an association between perioperative glycemic management and diabetes remission following bariatric surgery.
- 11 February 2016
- Published by Springer Nature in Current Diabetes Reports
- Vol. 16 (2) , 1-9
Post–Gastric Bypass Hypoglycemia
Obesity is a major public health problem worldwide. Obesity-related illnesses, such as coronary heart disease, type 2 diabetes, hypertension, dyslipidemia, stroke, sleep apnea, and several forms of cancer (endometrial, breast, and colon), contribute to a significant number of deaths in the USA. Bariatric surgery, including the Roux-en-Y gastric bypass (RYGB) procedure, has demonstrated significant improvements in obesity and obesity-related co-morbidities and is becoming more popular as the number of obese individuals rises. Despite the reported benefits of bariatric surgery, there are potential complications that physicians need to be aware of as the number of patients undergoing these procedures continues to increase. One challenging and potentially life-threatening complication that to date is not well understood is post-RYGB surgery hypoglycemia (PGBH). In this review, we will present the definition, historical perspective, diagnostic approach, currently available treatment options, and anecdotal assessment and treatment algorithm for this disorder.
- 11 February 2016
- Published by Springer Nature in Current Diabetes Reports
- Vol. 16 (2) , 1-9
Post–Gastric Bypass Hypoglycemia
Obesity is a major public health problem worldwide. Obesity-related illnesses, such as coronary heart disease, type 2 diabetes, hypertension, dyslipidemia, stroke, sleep apnea, and several forms of cancer (endometrial, breast, and colon), contribute to a significant number of deaths in the USA. Bariatric surgery, including the Roux-en-Y gastric bypass (RYGB) procedure, has demonstrated significant improvements in obesity and obesity-related co-morbidities and is becoming more popular as the number of obese individuals rises. Despite the reported benefits of bariatric surgery, there are potential complications that physicians need to be aware of as the number of patients undergoing these procedures continues to increase. One challenging and potentially life-threatening complication that to date is not well understood is post-RYGB surgery hypoglycemia (PGBH). In this review, we will present the definition, historical perspective, diagnostic approach, currently available treatment options, and anecdotal assessment and treatment algorithm for this disorder.